| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tao Ma, Xueliang Du, Joseph E Pick, Guangzhi Sui, Michael Brownlee, Eric Klan. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 40. 2013-01-17. PMID:23035082. |
glucagon-like peptide-1 (glp-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. |
2013-01-17 |
2023-08-12 |
mouse |
| Tao Ma, Xueliang Du, Joseph E Pick, Guangzhi Sui, Michael Brownlee, Eric Klan. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 40. 2013-01-17. PMID:23035082. |
its natural cleavage product glp-1(9-36)(amide) possesses distinct properties and does not affect insulin secretion. |
2013-01-17 |
2023-08-12 |
mouse |
| Guido Di Dalmazi, Uberto Pagotto, Renato Pasquali, Valentina Vicennat. Glucocorticoids and type 2 diabetes: from physiology to pathology. Journal of nutrition and metabolism. vol 2012. 2013-01-15. PMID:23316348. |
abnormalities in other hormones such as reduced secretion of the incretin glucagon-like peptide 1 (glp-1), hyperglucagonemia, and raised concentrations of other counterregulatory hormones also contribute to insulin resistance, reduced insulin secretion, and hyperglycaemia in type 2 diabetes. |
2013-01-15 |
2023-08-12 |
Not clear |
| Young Min Cho, Catherine E Merchant, Timothy J Kieffe. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & therapeutics. vol 135. issue 3. 2013-01-14. PMID:22659620. |
similar to gip, glp-1 is released from intestinal l-cells following food intake and potentiates glucose-dependent insulin secretion from β-cells. |
2013-01-14 |
2023-08-12 |
Not clear |
| Marzieh Salehi, Benedict Aulinger, David A D'Alessi. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes. vol 61. issue 11. 2013-01-14. PMID:22733799. |
the incretin effect, reflecting the enhancement of postprandial insulin secretion by factors including the intestinal hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide, increases in proportion to meal size. |
2013-01-14 |
2023-08-12 |
human |
| Marzieh Salehi, Benedict Aulinger, David A D'Alessi. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes. vol 61. issue 11. 2013-01-14. PMID:22733799. |
these findings indicate that the incretin contribution to postprandial insulin release is independent of glycemia in healthy individuals, despite differences in glp-1 secretion. |
2013-01-14 |
2023-08-12 |
human |
| Marcus Lin. Incretin therapy and its effect on body weight in patients with diabetes. Primary care diabetes. vol 6. issue 3. 2013-01-11. PMID:22613745. |
glucagon-like peptide 1 (glp-1) analogues and dipeptidyl peptidase-4 (dpp-4) inhibitors are two classes of treatments for type 2 diabetes, which enhance the well-known 'incretin effect' of increased insulin secretion in response to food intake. |
2013-01-11 |
2023-08-12 |
human |
| Sonya G Fonseca, Fumihiko Urano, Gordon C Weir, Jesper Gromada, Mark Burci. Wolfram syndrome 1 and adenylyl cyclase 8 interact at the plasma membrane to regulate insulin production and secretion. Nature cell biology. vol 14. issue 10. 2013-01-11. PMID:22983116. |
here we provide evidence that wfs1 is essential for glucose- and glucagon-like peptide 1 (glp-1)-stimulated cyclic amp production and regulation of insulin biosynthesis and secretion. |
2013-01-11 |
2023-08-12 |
Not clear |
| Dan Zhu, Yi Zhang, Patrick P L Lam, Subhankar Dolai, Yunfeng Liu, Erica P Cai, Diana Choi, Stephanie A Schroer, Youhou Kang, Emma M Allister, Tairan Qin, Michael B Wheeler, Cheng-Chun Wang, Wan-Jin Hong, Minna Woo, Herbert Y Gaisan. Dual role of VAMP8 in regulating insulin exocytosis and islet β cell growth. Cell metabolism. vol 16. issue 2. 2013-01-10. PMID:22841572. |
optimal insulin secretion required to maintain glucose homeostasis is the summation of total pancreatic islet β cell mass and intrinsic secretory capacity of individual β cells, which are regulated by distinct mechanisms that could be amplified by glucagon-like-peptide-1 (glp-1). |
2013-01-10 |
2023-08-12 |
mouse |
| Dan Zhu, Yi Zhang, Patrick P L Lam, Subhankar Dolai, Yunfeng Liu, Erica P Cai, Diana Choi, Stephanie A Schroer, Youhou Kang, Emma M Allister, Tairan Qin, Michael B Wheeler, Cheng-Chun Wang, Wan-Jin Hong, Minna Woo, Herbert Y Gaisan. Dual role of VAMP8 in regulating insulin exocytosis and islet β cell growth. Cell metabolism. vol 16. issue 2. 2013-01-10. PMID:22841572. |
we employed snare protein vamp8-null mice to demonstrate that vamp8 mediates insulin granule recruitment to the plasma membrane, which partly accounts for glp-1 potentiation of glucose-stimulated insulin secretion. |
2013-01-10 |
2023-08-12 |
mouse |
| Dan Zhu, Yi Zhang, Patrick P L Lam, Subhankar Dolai, Yunfeng Liu, Erica P Cai, Diana Choi, Stephanie A Schroer, Youhou Kang, Emma M Allister, Tairan Qin, Michael B Wheeler, Cheng-Chun Wang, Wan-Jin Hong, Minna Woo, Herbert Y Gaisan. Dual role of VAMP8 in regulating insulin exocytosis and islet β cell growth. Cell metabolism. vol 16. issue 2. 2013-01-10. PMID:22841572. |
we conclude that these vamp8-mediated events partly underlie the therapeutic actions of glp-1 on insulin secretion and β cell growth. |
2013-01-10 |
2023-08-12 |
mouse |
| Meir Mizrahi, Yehudit Shabat, Ami Ben Ya'acov, Gadi Lalazar, Tomer Adar, Victor Wong, Brian Muller, Grant Rawlin, Yaron Ila. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. Journal of inflammation research. vol 5. 2013-01-08. PMID:23293533. |
alleviation of insulin resistance and liver damage by oral administration of imm124-e is mediated by increased tregs and associated with increased serum glp-1 and adiponectin: results of a phase i/ii clinical trial in nash. |
2013-01-08 |
2023-08-12 |
cattle |
| M A Poreba, C X Dong, S K Li, A Stahl, J H Miner, P L Brubake. Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells. American journal of physiology. Endocrinology and metabolism. vol 303. issue 7. 2013-01-07. PMID:22871340. |
the antidiabetic intestinal l cell hormone glucagon-like peptide-1 (glp-1) enhances glucose-dependent insulin secretion and inhibits gastric emptying. |
2013-01-07 |
2023-08-12 |
mouse |
| Pyung-Hwan Kim, Minhyung Lee, Sung Wan Ki. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. Journal of controlled release : official journal of the Controlled Release Society. vol 162. issue 1. 2013-01-02. PMID:22705459. |
exendin-4, glucagon-like peptide 1 (glp-1) receptor agonist, is an exocrine hormone, which has potent insulinotropic actions similar to glp-1 such as stimulating insulin biosynthesis, facilitating glucose concentration dependent insulin secretion, slowing gastric emptying, reducing food intake and stimulating β-cell proliferation. |
2013-01-02 |
2023-08-12 |
mouse |
| R Nielsen, H Wiggers, M Halbirk, H Bøtker, J J Holst, O Schmitz, E Frandsen, S Nielsen, N Møller, H Nørrelun. Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 120. issue 5. 2012-12-31. PMID:22421983. |
metabolic effects of short-term glp-1 treatment in insulin resistant heart failure patients. |
2012-12-31 |
2023-08-12 |
Not clear |
| R Nielsen, H Wiggers, M Halbirk, H Bøtker, J J Holst, O Schmitz, E Frandsen, S Nielsen, N Møller, H Nørrelun. Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 120. issue 5. 2012-12-31. PMID:22421983. |
we studied the metabolic effects of 48-h glp-1 treatment in insulin resistant heart failure patients.in a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic hf patients with ihd received 48-h glp-1 and placebo-infusion. |
2012-12-31 |
2023-08-12 |
Not clear |
| Sanjay Kalra, Bharti Kalr. Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling. North American journal of medical sciences. vol 4. issue 12. 2012-12-31. PMID:23272306. |
counselling patients for glp-1 analogue therapy: comparing glp-1 analogue with insulin counselling. |
2012-12-31 |
2023-08-12 |
Not clear |
| Chien-Ping Liang, Seongah Han, Gang Li, Ira Tabas, Alan R Tal. Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment. Diabetes. vol 61. issue 10. 2012-12-28. PMID:22751695. |
increased signaling via glp-1 receptor or the crebp activator protein kinase a thus offers a way to rescue insulin-resistant macrophages from excessive er stress responses and apoptosis in insulin resistance and type 2 diabetes. |
2012-12-28 |
2023-08-12 |
mouse |
| Andrew C Calabria, Changhong Li, Paul R Gallagher, Charles A Stanley, Diva D De Leó. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. vol 61. issue 10. 2012-12-28. PMID:22855730. |
in preclinical studies, we showed that the glp-1 receptor antagonist exendin-(9-39) suppresses insulin secretion and corrects fasting hypoglycemia in sur-1(-/-) mice. |
2012-12-28 |
2023-08-12 |
mouse |
| Andrew C Calabria, Changhong Li, Paul R Gallagher, Charles A Stanley, Diva D De Leó. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. vol 61. issue 10. 2012-12-28. PMID:22855730. |
the primary outcome was blood glucose; secondary outcomes were insulin, glucagon, and glp-1. |
2012-12-28 |
2023-08-12 |
mouse |